Terbinafine Tablet
Product Images NDC 69097-859

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Terbinafine (NDC 69097-859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (250mg 30tabs)

These are Terbinafine tablets, USP containing 250mg of Terbinafine HCI. The tablets are dispensed with a patient information leaflet attached. The recommended storage temperature is between 20°C to 25°C. The tablets are manufactured by InvaGen Pharmaceuticals under Cipla Ltd. and distributed by Cipla USA, Inc. The lot number is not readable.*

FDA Label Image

Image 2 (Terbinafine Str)

FDA Label Image

Image 1 (Terbinafine Table)

This is a table presenting adverse events and discontinuation in a clinical trial comparing Terbinafine tablets with Placebo. The trial assesses the frequency of different adverse events such as headache, gastrointestinal symptoms (diarrhea, dyspepsia, abdominal pain, nausea, among others), dermatological symptoms (rash, pruritus, utticaria, among others), liver enzyme abnormalities, taste disturbance, and visual disturbance. The table reports the percentages of individuals experiencing each adverse event for both the Terbinafine and Placebo groups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.